Literature DB >> 2455494

Antigenic relationship between human and animal adenovirus hexons determined by means of monoclonal antibodies directed against bovine adenovirus type 2 hexon.

E Adám1, M Rusvai, A Lengyel, S Belák, I Nász.   

Abstract

Eight monoclonal antibodies (MAbs) directed against bovine adenovirus (BAV) 2 subtype B hexon were studied with 12 different hexon types of human adenoviruses (AV) belonging to 5 different subgenera using indirect ELISA, passive hemagglutination (HA), and gel diffusion assays. Two hexon types of animal origin (BAV3 and SAV16) were investigated, too. The reactivity of the MAb IV.F3 was the broadest, i.e. in ELISA and HA experiments it reacted with all hexon types studied. Based on these results as well as on the results of gel diffusion assays, this MAb should recognize the genus specific epitope of adenovirus hexons. Three MAbs (CA12, III.B11, and A12) could recognize different epitopes showing intersubgenus or intertype specificities. In spite of the fact, that all the eight MAbs proved to be bound by the hexon of ORT/111 (BAV2 subtype B) blotted onto nitrocellulose filter, four of the eight MAbs (BB7, BH5, II.A9, and IV.F5) failed to react with any human, and animal hexon types used in the present experiments. The results suggest that a gradient of antigenic relationship may exist between BAV2 hexon and the hexons of human serotypes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455494     DOI: 10.1007/bf01310903

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  14 in total

1.  Differentiation of adenovirus hexon epitopes with monoclonal antibodies by gel diffusion assays.

Authors:  E Adám; I Nász; A Lengyel; J Erdei; J Fachet
Journal:  Mol Immunol       Date:  1985-08       Impact factor: 4.407

2.  Grouping of monoclonal antibodies to adenovirus hexons by their cross-reactivity.

Authors:  E Adám; A Lengyel; M Takács; J Erdei; J Fachet; I Nász
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

3.  Phylogenetic relationships between adenoviruses as inferred from nucleotide sequences of inverted terminal repeats.

Authors:  M Shinagawa; Y Iida; A Matsuda; T Tsukiyama; G Sato
Journal:  Gene       Date:  1987       Impact factor: 3.688

4.  An adenovirus isolated from sheep and its relationship to type 2 bovine adenovirus.

Authors:  S Belák; V Pálfi
Journal:  Arch Gesamte Virusforsch       Date:  1974

5.  Proposal for subgrouping of bovine adenoviruses.

Authors:  A Bartha
Journal:  Acta Vet Acad Sci Hung       Date:  1969

6.  Characterization of monoclonal antibodies to adenovirus type 35 hexon.

Authors:  E Adám; A Lengyel; C S Kerékgyártó; J Erdei; J Fachet; I Nász
Journal:  Acta Virol       Date:  1988-09       Impact factor: 1.162

7.  A sensitive method for detection of polyclonal and monoclonal antibodies against the adenovirus hexon.

Authors:  A Lengyel; E Adám; I Nász; J Erdei; J Fachet
Journal:  Acta Virol       Date:  1985-09       Impact factor: 1.162

8.  Comparative studies of adenovirus hexon antigens.

Authors:  I Nász; A Lengyel; I Cserba
Journal:  Arch Gesamte Virusforsch       Date:  1972

9.  Immunological relationships between capsid components of adenoviruses of different host cell species origin.

Authors:  E Norrby; R G Marusyk; G Wadell
Journal:  Can J Microbiol       Date:  1971-09       Impact factor: 2.419

10.  Studies on the antigenic relationship between bovine subgroup 2 and conventional mammalian adenoviruses using immunofluorescence.

Authors:  B M Adair; E R McKillop; J B McFerran; D Todd
Journal:  Vet Microbiol       Date:  1983-04       Impact factor: 3.293

View more
  2 in total

1.  Antigenic homogeneity among the adenovirus hexon types of subgenus C.

Authors:  E Adám; I Nász; A Lengyel
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

2.  Characterization of adenovirus hexons by their epitope composition.

Authors:  E Adám; I Nász; A Lengyel
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.